About
About
News
- Details
Jason McLellan has been named the recipient of the International Vaccine Institutes Bioscience Park MahnHoon Award for his role in the development of numerous vaccines.
- Details
Drug candidate developed by Everett Stone and his team is effective in mice with cancers of skin, bladder, blood and colon.
- Details
Every year, millions of people become sickened by RSV, and more than 100,000 die. New vaccines with a connection to UT Austin may help turn those numbers around.
- Details
A structural biologist at UT Austin who played a key role in the development of COVID-19 vaccines has received the first Research Impact Award.
- Details
Alone, this target might not be strong enough to directly block infection, but might be used to jump-start or boost an immune response.
- Details
Jason McLellan, a structural biologist at The University of Texas at Austin, is being honored today with the announcement of two highly prestigious awards—the National Academy of Sciences (NAS) Award in Molecular Biology and the Norman Hackerman Award in Chemical Research from the Welch Foundation.
- Details
Nearly two years after COVID-19 vaccines entered widespread use, featuring technology from researchers at The University of Texas at Austin, the Cockrell School of Engineering and the College of Natural Sciences have launched Texas Biologics, a cross-disciplinary effort made up of world-renowned faculty members and researchers working across all areas of therapeutics.
- Details
New research could pave the way for a vaccine for a common respiratory virus.
- Details
Several years ago, a promising therapeutic using stem cell factor (SCF) emerged that could potentially treat a variety of ailments, such as ischemia, heart attack, stroke and radiation exposure. However, during clinical trials, numerous patients suffered severe allergic reactions and development of SCF-based therapeutics stopped. A research team led by engineers at The University of Texas at Austin has developed a related therapeutic that they say avoids these major allergic reactions while maintaining its therapeutic activity.
- Details
University of Texas at Austin molecular biosciences professor Jason McLellan was selected as a finalist for the 2022 Blavatnik National Awards for Young Scientists.